ReviewImmunology2015
New clinical advances in immunotherapy for the treatment of solid tumours.
Review in Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.Cancer immunology, immunotherapy : CII · 2026Article
- Recent advancements in lung cancer research: a narrative review.Translational lung cancer research · 2025Review
- Immune profiling of mouse lung adenocarcinoma paraffin tissues using multiplex immunofluorescence panel: a pilot study.Laboratory animal research · 2024Article
- In Vitro Cancer Models: A Closer Look at Limitations on Translation.Bioengineering (Basel, Switzerland) · 2022Review
- Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.Therapeutic advances in medical oncology · 2022Article
- First-line nivolumab plus ipilimumab or chemotherapyTherapeutic advances in medical oncology · 2022Article
- A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.Frontiers in oncology · 2022Review
- Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- Article
- Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group.Gerontology · 2021Review
- Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.PloS one · 2021Article
- Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer.Journal of translational medicine · 2020Review
- Article
- Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.British journal of anaesthesia · 2020Review
- Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).Advances in therapy · 2019Review
- Magnetic Resonance Colonography Enables the Efficacy Assessment of Immune Checkpoint Inhibitors in an Orthotopic Colorectal Cancer Mouse Model.Translational oncology · 2019Article
- The lung microenvironment: an important regulator of tumour growth and metastasis.Nature reviews. Cancer · 2019Review
- Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.JCI insight · 2018Article
- Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs.Clinical and translational medicine · 2018Article
- Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in understanding the mechanisms of cancer cells for evading the immune system surveillance, including how the immune system modulates the phenotype of tumours, have allowed the development of new therapies that benefit from this complex cellular network to specifically target and destroy cancer cells. Immunotherapy researchers have mainly focused on the discovery of tumour antigens that could confer specificity to immune cells to detect and destroy cancer cells, as well as on the mechanisms leading to an improved activation of effector immune cells. The Food and Drug Administration approval in 2010 of ipilumumab for melanoma treatment and of pembrolizumab in 2014, monoclonal antibodies against T-lymphocyte-associated antigen 4 and programmed cell death 1, respectively, are encouraging examples of how research in this area can successfully translate into clinical use with promising results. Currently, several ongoing clinical trials are in progress testing new anti-cancer therapies based on the enhancement of immune cell activity against tumour antigens. Here we discuss the general concepts related to immunotherapy and the recent application to the treatment of cancer with positive results that support their consideration of clinical application to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.